Shanghai Pharmaceuticals Holding (02607): Net profit attributable to shareholders for the first three quarters was RMB4.586 billion, down 10.90% year on year.

Shanghai Pharmaceuticals Holding (02607) announced that for January-September 2026, the company achieved operating revenue of RMB222.964 billion (currency: RMB, same below), up 3.67% year on year. Of this: pharmaceutical industry achieved sales revenue of RMB18.989 billion, up 4.54% year on year; pharmaceutical commerce achieved sales revenue of RMB203.975 billion, up 3.59% year on year. For January-September 2026, the company achieved net profit attributable to shareholders of the listed company of RMB4.586 billion, down 10.90% year on year; net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was RMB3.374 billion, up 25.02% year on year. For January-September 2026, the company's net operating cash flow was an inflow of RMB5.347 billion, up 127.54% year on year, sustaining high-quality development.